Indiana Medicaid

Does Indiana Medicaid cover Zepbound?

Quick answer · Weight Loss

Indiana Medicaid does not cover it for weight loss on Medicaid.

  • Medicaid: Not covered. Document explicitly states 'ZEPBOUND (TIRZEPATIDE) (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS)'. No weight loss PA criteria are established; coverage is only available for the OSA indication.

Last verified June 4, 2026. Policy effective July 1, 2026. Source: 20260701_Public-Facing_GLP-1%20RA-GIP-Combinations_PA_Final.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Indiana Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Not covered

Document explicitly states 'ZEPBOUND (TIRZEPATIDE) (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS)'. No weight loss PA criteria are established; coverage is only available for the OSA indication.

Policy note: Explicitly not covered for weight loss as a standalone indication. Header explicitly states 'NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS.'

Policy effective July 1, 2026 · verified June 4, 2026 · source: 20260701_Public-Facing_GLP-1%20RA-GIP-Combinations_PA_Final.pdf

Zepbound for Osa

What Indiana Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • A1C no higher than 6.5%
  • Prescribed by or in consultation with a specialist
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Moderate-to-Severe OSA with Obesity — Current AHI >=15

All of:

  • Member is 18 years of age or older
  • Diagnosis of moderate to severe OSA (AHI >=15 events/hour) in individuals with obesity
  • Documented BMI >= 30 kg/m2 with baseline weight before initiating Zepbound (chart documentation within past 3 months)
  • AHI >=15 events/hour on PSG or HSAT reviewed and interpreted by sleep medicine-certified physician (documentation from study obtained within past year)
  • Member does not have Type 1 or Type 2 diabetes mellitus
  • HbA1c < 6.5% (chart documentation within past 3 months)
  • No diagnosis of central or mixed sleep apnea with >=50% mixed/central apneas/hypopneas (prescriber attestation)
  • Member will use in combination with reduced calorie diet and increased physical activity
  • No concurrent use with another GLP-1 RA or combination product (including tirzepatide-containing products)
  • Dose does not exceed 15 mg/week

Moderate-to-Severe OSA with Obesity — Prior AHI >=15 on PAP Therapy

All of:

  • Member is 18 years of age or older
  • Diagnosis of moderate to severe OSA (AHI >=15 events/hour) in individuals with obesity
  • Documented BMI >= 30 kg/m2 with baseline weight before initiating Zepbound (chart documentation within past 3 months)
  • Prior AHI >=15 events/hour on PSG or HSAT reviewed and interpreted by sleep medicine-certified physician (documentation required)
  • Member does not have Type 1 or Type 2 diabetes mellitus
  • HbA1c < 6.5% (chart documentation within past 3 months)
  • No diagnosis of central or mixed sleep apnea with >=50% mixed/central apneas/hypopneas (prescriber attestation)
  • Member will use in combination with reduced calorie diet and increased physical activity
  • No concurrent use with another GLP-1 RA or combination product (including tirzepatide-containing products)
  • Dose does not exceed 15 mg/week

Plus any one of:

  • Currently utilizing PAP therapy (CPAP or BiPAP) with documented adherence within past 90 days (>=4 hours/night for >=70% of nights in a 30-day period, supported by PAP therapy report or chart note)
  • Prescriber has provided valid medical justification why member cannot use PAP therapy (e.g., intellectual disabilities)

Documentation to bring

  • Chart documentation confirming BMI >= 30 kg/m2 and baseline weight obtained within past 3 months
  • PSG or HSAT report with AHI >=15 events/hour reviewed and interpreted by sleep medicine-certified physician (obtained within past year), OR prior PSG/HSAT report with AHI >=15 plus PAP therapy adherence documentation or medical justification for PAP inability
  • HbA1c lab result < 6.5% obtained within past 3 months
  • Prescriber attestation of no T1D or T2D diagnosis
  • Prescriber attestation of no central or mixed sleep apnea (>=50% mixed/central apneas/hypopneas)
  • PAP therapy adherence report (within past 90 days showing >=4 hours/night for >=70% of nights in 30-day period) if using the PAP pathway, OR prescriber medical justification for PAP inability
  • Prescriber attestation of diet/physical activity use
  • Prescriber attestation of no concurrent GLP-1 RA or tirzepatide-containing products

Quantity limits

  • all strengths — max 15 mg/week

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At first reauthorization (therapy >1 year and <2 years): documented reduction in AHI from baseline (PSG, HSAT, or CPAP/BiPAP sleep data obtained within past 3 months). At all reauthorizations: documented meaningful weight loss of at least 5% from baseline, prescriber attests no T1D or T2D, prescriber attests no central or mixed sleep apnea diagnosis, no concurrent GLP-1 RA or tirzepatide-containing products, dose does not exceed 15 mg/week, history of requested agent at least 84 days within past 112 days, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes excluded
  • HbA1c >=6.5% excluded
  • Central or mixed sleep apnea with >=50% mixed/central apneas/hypopneas excluded
  • No concurrent use with another GLP-1 RA or combination product including tirzepatide-containing products
  • Dose must not exceed 15 mg/week
  • Weight loss as the sole indication is explicitly not covered
  • Type 1 diabetes

Policy note: Document states 'ZEPBOUND (TIRZEPATIDE) (NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS).' OSA-only indication: members must NOT have T1D or T2D and must have HbA1c <6.5%. Two pathways: (1) current PSG/HSAT with AHI >=15 within past year; (2) prior PSG/HSAT with AHI >=15 and current PAP therapy adherence or medical justification for PAP non-use. PAP adherence defined as >=4 hours/night for >=70% of nights within a 30-day period. At first renewal only (therapy 1-2 years), AHI reduction from baseline must be documented. At ALL renewals, >=5% weight loss from baseline required. Specialist required: sleep medicine-certified physician must review and interpret the diagnostic sleep study.

Policy effective July 1, 2026 · verified June 4, 2026 · source: 20260701_Public-Facing_GLP-1%20RA-GIP-Combinations_PA_Final.pdf

Why Zepbound requests get denied by Indiana Medicaid

Based on what this policy asks for. Fix these before the first submission.

  1. Your plan's benefit excludes weight loss medications. A prior authorization cannot override a benefit exclusion — ask about a formulary exception or a different covered pathway.
  2. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. Prescriber isn't the specialist the plan requires.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

Indiana Medicaid has separate Zepbound policies that don't depend on the weight loss benefit:

  • Osa — covered on Medicaid.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does Indiana Medicaid cover Zepbound?
Indiana Medicaid does not cover it for weight loss on Medicaid.
How long does a Zepbound approval last with Indiana Medicaid?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does Indiana Medicaid require to renew Zepbound?
At least 5% weight loss from the starting weight, At first reauthorization (therapy >1 year and <2 years): documented reduction in AHI from baseline (PSG, HSAT, or CPAP/BiPAP sleep data obtained within past 3 months). At all reauthorizations: documented meaningful weight loss of at least 5% from baseline, prescriber attests no T1D or T2D, prescriber attests no central or mixed sleep apnea diagnosis, no concurrent GLP-1 RA or tirzepatide-containing products, dose does not exceed 15 mg/week, history of requested agent at least 84 days within past 112 days, and at least 12 weeks on therapy before the first renewal.
What if my plan excludes weight loss medications?
Indiana Medicaid has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?
This page reflects Indiana Medicaid's written policy as of July 1, 2026, last verified against the source document on June 4, 2026.

Other medications under Indiana Medicaid

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Indiana Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.